<DOC>
	<DOCNO>NCT01708213</DOCNO>
	<brief_summary>The protocol hypothesis treatment Aline HA™ safe 6 month determine clinical assessment treatment sit routine track adverse event .</brief_summary>
	<brief_title>Safety Evaluation Aline HA , Implanted Cross-Linked HA Device</brief_title>
	<detailed_description>A multi-center , open-label , prospective study implant cross-linked HA device , Aline HA , soft tissue augmentation , treat one anatomic feature 100 subject 6 month .</detailed_description>
	<criteria>1 . The patient must ≥ 21 ≤ 70 year age . 2 . The patient must willing able provide inform consent . 3 . The patient must able read . 4 . The patient willing able comply study protocol . 5 . The patient seek soft tissue augmentation 6 . The patient pretreatment Wrinkle Severity Score ( WSS ) ≥ 2 NLF treat . 7 . The patient agree followup examination 6 month post final treatment . 1 ) The patient ( plan ) cosmetic procedure treat intend treatment area , : 1 . Ablative nonablative resurfacing procedure include limited medium depth deep chemical peeling , dermabrasion , laser resurface fractional resurfacing would affect treatment area within last 12 month . 2 . Laser light base therapy would affect treatment area within last 6 month . 3 . Face , neck brow lift surgical procedure head neck would affect treatment area last 18 month . 4 . Nonpermanent dermal filler treatment treatment area within last 9 month . 5 . Permanent implant dermal filler treatment treatment area point time . 6 . Neurotoxin treatment would affect treatment area last 6 month , treatment area eye . 7 . Neurotoxin treatment would affect treatment area last 9 month , treatment area eye . 2 ) The patient plan use pharmaceutical ( topical oral ) antiwrinkle product product ( e.g. , topical retinoids , hormone cream ) affect inflammation treatment area within 30 day study 3 ) The patient inflammatory infectious skin condition unhealed wound treatment area . 4 ) The patient cancerous precancerous lesion and/or radiation exposure treatment area last 24 month . 5 ) The patient history anaphylaxis , multiple severe allergy , atopy , allergic lidocaine amidebased anesthetic , hyaluronic acid product , Streptococcal protein proteins gram positive organism . 6 ) The patient history significant bleeding disorder . 7 ) The patient scleroderma fibrotic tissue disease . 8 ) The patient female child bear potential and/or pregnant lactate use medically effective birth control , hormonal method use least 30 day prior implantation , barrier method condom spermicide use least 14 day prior implantation . 9 ) The patient use Legally Authorized Representative . 10 ) The patient employee employee 's family member either Study Sponsor Study Site .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>soft tissue</keyword>
	<keyword>augmentation</keyword>
	<keyword>correction</keyword>
	<keyword>wrinkle</keyword>
</DOC>